TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02378805
Drug: Angiotensin-receptor blocker (ARB)
Approvals — FDA: no, EMA: no, PMDA: no
Description: observational study
Study: NCT02378805
Drug: HMG-Coenzyme inhibitor (statin)
Normalized name: HMG CoA reductase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: observational study
Study: NCT02378805
Drug: Spironolactone or Finerenone
Normalized name: Finerenone
DrugBank: Finerenone (DB16165)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: observational study
Study: NCT03868540
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet
Study: NCT03141554
Drug: 1% Betadine® PVP-I based mouth wash and gargle,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% Betadine® PVP-I based mouth wash and gargle
Study: NCT00612079
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 x 4mg Placebo
Study: NCT01160211
Drug: Aromatase Inhibitor
Normalized name: Aromatase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatase inhibitor (either letrozole, anastrozole, or exemestane) of investigator's choice given by mouth once daily
Study: NCT04072380
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Tablets
Study: NCT02664805
Drug: LEO 124249 ointment
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ointment
Study: NCT02664805
Drug: LEO 124249 ointment vehicle
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ointment vehicle
Study: NCT02420665
Drug: Acetic Acid
Normalized name: Acetic acid
DrugBank: Acetic acid (DB03166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3 - 5% added to cervix before visual inspection.
Study: NCT04641754
Drug: WX-0593 Tablets
Normalized name: WX-554
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets, 60 mg→180mg, quaque die（QD）
Study: NCT00349882
Drug: Marketed multipurpose disinfection regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02523274
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vegetable-based cellulose
Study: NCT03786809
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients of the placebo group will use placebo once a day for 28 days
Study: NCT01832363
Drug: HXe MRI guided treatment sequence for BT
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: HXe MRI consists in imaging the inhaled xenon gas inside the human lungs during a short breath-hold. High resolution 3D maps of the HXe distribution inside the lungs provide information regarding ventilation of the lungs, as the signal is proportional to the local concentration of HXe. A high MRI signal translates in unobstructed ventilation, while ventilation defects appear as dark regions on the map. HXe MRI will be performed pre and post bronchodilator in order to determine the airways which potentially are the most responsive to BT treatment. All HXe MRI images will be repeated within the same day for consistency check and after three weeks to study temporal variability. The reactivity of the airways will establish the treatment order, with the most problematic airways to be treated in the first BT session (not to exceed six).
Study: NCT00761150
Drug: ABT-712
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-712 extended-release tablet
Study: NCT00761150
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet
Study: NCT02734290
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 2000mg every two weeks by mouth twice each day on days 1-7 of each 2 week cycle.
Study: NCT02424214
Drug: Ca Ionophore
Normalized name: iodophors
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02184351
Drug: Mycelex® troches
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04763876
Drug: Ketorolac Injection 15 mg
Normalized name: ketorolac Injection
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A single dose of 15 mg ketorolac administered intramuscularly.
Study: NCT04763876
Drug: Ketorolac Injection 60 mg
Normalized name: ketorolac Injection
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A single dose of 60 mg ketorolac administered intramuscularly.
Study: NCT03018665
Drug: BIAsp30
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection，fit dosage twice a day in three months
Study: NCT03402620
Drug: Gonadotropins
Normalized name: GONADOTROPINS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human menopausal gonadotropin 75 IU ampoules start at cycle day 2
Study: NCT02354976
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching to Omega-3 carboxylic acids (olive oil)
Study: NCT02354976
Drug: Omega-3 carboxylic acid
Normalized name: omega-3 carboxylic acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g administered as 4 x 1 g capsules
Study: NCT02354976
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching to fenofibrate 200mg
Study: NCT03002376
Drug: REGN2810
Approvals — FDA: no, EMA: no, PMDA: no
Description: REGN2810 treatment
Study: NCT04209218
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 ml normal saline) is administered before anesthesia induction.
Study: NCT00913250
Drug: Serum containing Avonex
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60mcg IM dose of serum containing Avonex on Day 1, followed by 60mcg IM dose of serum free Avonex on Day 15
Study: NCT00913250
Drug: Serum Free Avonex
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60mcg IM dose of serum free Avonex on Day 1, followed by 60mcg IM dose of serum containing Avonex on Day 15.
Study: NCT03690141
Drug: eFT508
Approvals — FDA: no, EMA: no, PMDA: no
Description: This Phase 2 study examines the efficacy, safety, tolerability, and PK of tomivosertib (eFT508) in advanced CRPC patients who have documented PSA progression on treatment with apalutamide and/or abiraterone and/or enzalutamide and for whom no suitable curative therapy exists.
Study: NCT00084773
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01247896
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single Dose Placebo
Study: NCT03963999
Drug: Contrast Enhanced Ultrasound (CEUS)
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast-enhanced ultrasound (CEUS) uses an intravenous injection of microbubble contrast agent.
Study: NCT00773552
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tab PO Qday x 90 days
Study: NCT01857310
Drug: Placebo Comparator: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00353028
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00993135
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00580333
Drug: doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative: Given intravenously for four 2-week cycles
Study: NCT00580333
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Postoperative: Given intravenously for four two-week cycles
Study: NCT01931137
Drug: insulin 338 (GIPET I)
Normalized name: insulin isophane, human Injectable Suspension [Humulin I]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose level of 8100 nmol will be orally administered as one tablet per dose.
Study: NCT00267007
Drug: PROCRIT 40,000 IU QW
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epoetin alpha (PROCRIT) 40,000 IU every week (QW) for 18 weeks (IV or SC)
Study: NCT00267007
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Equivalent volume to PROCRIT (1 mL) administered (QW) for 18 weeks (IV or SC)
Study: NCT00423488
Drug: Simvastatin 20 mg
Normalized name: simvastatin 20 MG
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 x 20-mg tablet, provided as open-label study treatment
Study: NCT00972478
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00972478
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00423488
Drug: Simvastatin 20 mg
Normalized name: simvastatin 20 MG
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 x 20-mg tablet, provided as blinded study treatment
Study: NCT00056082
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib daily for 12 months
Study: NCT02633761
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo followed in 24 hours by 200mcg buccal misoprostol every 3 hours.
Study: NCT03118765
Drug: GSP304 (tiotropium bromide) Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily (QD) oral inhalation using a nebulizer
Study: NCT03118765
Drug: GSP304 Placebo Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily (QD) oral inhalation using a nebulizer
Study: NCT03118765
Drug: Spiriva® Respimat® inhalation spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily (QD) oral inhalation
Study: NCT03398278
Drug: OXYCONTIN®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally taking OXYCONTIN® 40mg in fast state
Study: NCT02440100
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo which will be given as oral suspension, once a day for 14 days
Study: NCT00814125
Drug: Nolvadex placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00814125
Drug: Arimidex placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00307879
Drug: Drug: G-CSF (Dong-A pharmaceutical, Seoul, Korea)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04749615
Drug: Saline Control Periarticular Injection (PAI)
Approvals — FDA: no, EMA: no, PMDA: no
Description: equal volume of saline will be used in place of analgesics used in PAI injections
Study: NCT02127060
Drug: Placebo drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: for 1 month postoperative period, placebo medication administered orally to the patients.
Study: NCT01235871
Drug: SB1578
Approvals — FDA: no, EMA: no, PMDA: no
Description: JAK2 Inhibitor
Study: NCT01235871
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control arm
Study: NCT00000253
Drug: 10% N2O
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00000253
Drug: 20% N2O
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00000253
Drug: 30% N2O
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00000253
Drug: 40% N2O
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00006157
Drug: Desipramine
Normalized name: Desipramine
DrugBank: Desipramine (DB01151)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02252497
Drug: Placebo comparator : physiologic serum
Approvals — FDA: no, EMA: no, PMDA: no
Description: * 1g Intra Venous just before surgery~* Then infusion of 1g of physiologic serum over eight hours
Study: NCT03292861
Drug: Corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg IV methylprednisolone immediately post-operatively x 3 doses q12hrs, then switching to oral prednisone at 1.0 mg/kg/day po divided into bid doses that are rounded off to the next higher 5 mg increment. For example, a 76 kg person would should be dosed at 38 mg po bid, which rounded off to the next 5 mg increment would be 40 mg po bid. (Equivalent dosing via an alternative route may be used if pos not tolerated or contraindicated). Prednisone will be tapered by 10 mg qd until the dose of 10 mg po bid is reached.
Study: NCT00964080
Drug: MBP-426/Leucovorin/5-FU
Approvals — FDA: no, EMA: no, PMDA: no
Description: MBP-426 will be administered at a dose of 170 mg/m2 every three weeks. Leucovorin will be administered at a dose of 400 mg/m2 after the MBP-426 infusion and in the absence of allergy/infusion reaction. 5-FU is administered concurrently with the leucovorin infusion and after the MBP-426 administration as a 46-hour continuous infusion of 2400 mg/m2.
Study: NCT02715466
Drug: Balanced electrolyte solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterofundin ISO
Study: NCT04071626
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral tablet once a day for 12 weeks
Study: NCT01715415
Drug: ABT-450/r/ABT-267, ABT-333
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
Study: NCT01715415
Drug: Placebo for ABT-333
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT03736720
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03736720
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03446261
Drug: Rosuvamibe® Tab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 5mg/ezetimibe 10mg qd for 8 weeks
Study: NCT03446261
Drug: Monorova® Tab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 10mg qd for 8 weeks
Study: NCT01112683
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: These are identically-looking pills to those in the Memantine Arm.
Study: NCT01754909
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, once a day, orally, as 2.5 , 5, or 10 mg tablets to be given in escalating doses, to subjects undergoing radiotherapy for lung cancer
Study: NCT01261832
Drug: antiplatelet therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy is defined as combination therapy with aspirin and clopidogrel and triple antiplatelet therapy is defined as combination therapy with aspirin,clopidogrel and cilostazol.
Study: NCT03170232
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is a white film coated oval shaped tablet. It will be provided in a labeled HDPE bottle with desiccant.
Study: NCT03170232
Drug: Rescue medication
Normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects may continue to use rescue medication(s) via their usual route. Allowed medications are: short acting beta agonists (SABA) (e.g., albuterol/salbutamol); short acting muscarinic antagonists (SAMA) (e.g., ipratropium); short acting combination (SABA/SAMA) bronchodilators, (e.g. Duoneb, Combivent)
Study: NCT00874757
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Healthy subjects received rosuvastatin 20 mg orally for 3 weeks. Inflammatory markers measured pre- and post- rosuvastatin treatment.
Study: NCT01253889
Drug: Glucose 25% oral solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5ml of 25% glucose (26-31 weeks gestational age group) or 1.0 ml of 25% glucose (32-42 weeks gestational age group). This application can be repeated if necessary to a maximum of four times, adding up to max 2ml of 25% glucose in the 26-31 weeks gestational age group or 4ml of 25% glucose in the 32-42 weeks gestational age group.
Study: NCT04584697
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diluent solution
Study: NCT03724747
Drug: BAY2315497 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 2315497 Injection comprises 3 components: the PSMA-specific monoclonal antibody (mAb), the mAb-chelator conjugate, and the thorium-227 labeled mAb-chelator conjugate. BAY 2315497 Injection will be administered on Day 1 of each treatment cycle.
Study: NCT00883844
Drug: Nucleos(t)ide analogue treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with one of the approved nucleos(t)ide analogues
Study: NCT01419067
Drug: ^1^8F-fluorodeoxyglucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a contrast media that will be given intravenously to aid in tumor visualization.
Study: NCT01419067
Drug: ^1^1C-methionine
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a contrast media that will be given intravenously to aid in tumor visualization.
Study: NCT02830230
Drug: Tab cefixime,Tab Azithromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: The women with clinical cervicitis will receive treatment for cervicitis.
Study: NCT01390506
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0,9% sodium chloride is administered intravenously
Study: NCT00080288
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets once daily
Study: NCT02488902
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02719314
Drug: Glucocorticoid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucocorticoid treatment
Study: NCT02979522
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin infusion
Study: NCT01246973
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 placebo capsules taken orally 3 times/day throughout course of radiation treatments plus one week
Study: NCT04313023
Drug: PUL-042 Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20.3 µg Pam2 : 29.8 µg ODN/mL (50 µg PUL-042) PUL-042 Inhalation Solution
Study: NCT04313023
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile saline for inhalation
Study: NCT00525564
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo diskus inhalation powder
Study: NCT04268784
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single and repeating oral dose(s)
Study: NCT02100527
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo matching 200 mg (as 2x100 mg tablets) BID for 6 weeks
Study: NCT03197571
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
Study: NCT03197571
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
Study: NCT03197571
Drug: 5Fluorouracil (5-FU)
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluoro-2,4 (1H,3H)-pyrimidinedione
Study: NCT03197571
Drug: leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Calcium N-\[p-\[\[\[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl\]methyl\]amino\]benzoyl\]-L-glutamate (1:1)
Study: NCT01837420
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00818831
Drug: QBI-139
Approvals — FDA: no, EMA: no, PMDA: no
Description: QBI-139 is being administered once a week over a two hour infusion in escalating doses.
Study: NCT00003682
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01230125
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instill study medication into the study eye per dosing instructions for 14 days
Study: NCT00082472
Drug: Doxorubicin HCl Inhalation Solution
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02598622
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is taken 2 times a day for days 1 through 21.
Study: NCT00814216
Drug: QAV680
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00814216
Drug: Matching placebo for QAV680
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01037101
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg placebo administered 30 minutes before the session
Study: NCT03197662
Drug: Matched Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject will receive a dose of 16 IU QD, and will be instructed to inhale 2 puffs per nostril every day (4 IU each). If needed, treatment will be titrated due to side effects or non-response.
Study: NCT00606879
Drug: SGX523 Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a dose escalation study
Study: NCT02123069
Drug: Acetylcholine
Normalized name: Acetylcholine
DrugBank: Acetylcholine (DB03128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylcholine will be infused into the brachial catheter while blood flow levels in the forearm are measured. Acetylcholine will be infused at the following doses: 1.0, 2.0, 4.0, and 8.0 ug/100 ml tissue/min for 2 minutes each.
Study: NCT02123069
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norepinephrine will be infused into the brachial catheter while blood flow levels in the forearm are measured. Norepinephrine will be infused at the following doses: 1.0, 2.0, 4.0, and 8.0 ug/100 ml tissue/min for 2 minutes each.
Study: NCT03068910
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spironolactone is an androgen-receptor blocker commonly used (off-label) for hyperandrogenism. The spironolactone dose will be 50 mg taken orally twice daily (for two weeks before admission to the Clinical Research Unit).
Study: NCT03068910
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo contains only inert ingredients and is not expected to exert any direct physiological effects.
Study: NCT01216605
Drug: Syntocinon 24 IU
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01216605
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00914303
Drug: AZD3241
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Tablet, Repeated Administration
Study: NCT00914303
Drug: Placebo Tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Tablet. Repeated Administration
Study: NCT02496221
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is a single-use fixed dose, fully disposable pen injector system for SC delivery of 0.5 mL injector volume in the abdomen
Study: NCT02587247
Drug: TF2 antibody/68Ga-IMP-288
Approvals — FDA: no, EMA: no, PMDA: no
Description: TF2 antibody coupled with 68Ga-IMP-288